ArticlePloS one2025
Glycemic variability and mortality in patients with aortic diseases: A multicenter retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glycemic variability does not provide incremental prognostic value for in-hospital death in community-acquired pneumonia patients: conventional clinical variables dominate.BMC pulmonary medicine · 2026Article
- Prognostic value of mean glycemia and glycemic variability in medical, surgical, and cardiovascular intensive care units at a Lebanese tertiary care center.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe influence of glycemic variability (GV), defined as blood glucose fluctuations, on short-term mortality in patients with aortic diseases, such as aneurysms and dissections, remains understudied. This study evaluates the association between GV and mortality, explores non-linear patterns, and determines a GV threshold predictive of mortality risk.
methodsA retrospective analysis of 2,441 patients with aortic aneurysm or dissection from the MIMIC IV and eICU-CRD databases was performed. Key variables, including demographics, clinical characteristics, comorbidities, laboratory findings, and treatments, were assessed. Logistic and Cox regression models, smooth curve fitting, and subgroup analyses examined associations between GV and ICU and 30-day mortality.
resultsICU mortality occurred in 165 patients (6.8%), and 30-day mortality in 235 patients (9.6%). Increased GV was linearly associated with ICU mortality risk (P for non-linearity = 0.666). For 30-day mortality, a U-shaped relationship was observed, with minimal risk at a GV index of 0.2047 (P for non-linearity = 0.041). Adjusted models confirmed these findings (ICU mortality: OR = 1.15, 95% CI = 1.03-1.30, 30-day mortality: HR = 1.10, 95% CI = 1.03-1.18).
conclusionsGV is significantly associated with short-term mortality in aortic disease patients, with a U-shaped pattern for 30-day mortality and an optimal threshold of 0.2047. These findings underscore the importance of tailored glucose management strategies and call for further research into underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.